In the past week, OCUL stock has gone down by -4.28%, with a monthly decline of -12.15% and a quarterly plunge of -21.40%. The volatility ratio for the week is 4.76%, and the volatility levels for the last 30 days are 4.94% for Ocular Therapeutix Inc The simple moving average for the last 20 days is -5.86% for OCUL’s stock, with a simple moving average of -15.67% for the last 200 days.
Is It Worth Investing in Ocular Therapeutix Inc (NASDAQ: OCUL) Right Now?
OCUL has 36-month beta value of 1.34. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for OCUL is 132.36M, and currently, short sellers hold a 8.76% ratio of that float. The average trading volume of OCUL on February 28, 2025 was 891.96K shares.
OCUL) stock’s latest price update
Ocular Therapeutix Inc (NASDAQ: OCUL)’s stock price has gone decline by 0.00 in comparison to its previous close of 6.94, however, the company has experienced a -4.28% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-02-24 that BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024.
Analysts’ Opinion of OCUL
TD Cowen, on the other hand, stated in their research note that they expect to see OCUL reach a price target of $11, previously predicting the price at $7. The rating they have provided for OCUL stocks is “Buy” according to the report published on June 20th, 2024.
Piper Sandler gave a rating of “Overweight” to OCUL, setting the target price at $15 in the report published on May 31st of the previous year.
OCUL Trading at -12.96% from the 50-Day Moving Average
After a stumble in the market that brought OCUL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.06% of loss for the given period.
Volatility was left at 4.94%, however, over the last 30 days, the volatility rate increased by 4.76%, as shares sank -11.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.93% lower at present.
During the last 5 trading sessions, OCUL fell by -4.28%, which changed the moving average for the period of 200-days by +18.84% in comparison to the 20-day moving average, which settled at $7.37. In addition, Ocular Therapeutix Inc saw -18.74% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OCUL starting from Dugel Pravin, who sale 21,475 shares at the price of $6.87 back on Feb 24 ’25. After this action, Dugel Pravin now owns 3,520,318 shares of Ocular Therapeutix Inc, valued at $147,533 using the latest closing price.
Heier Jeffrey S., the Chief Scientific Officer of Ocular Therapeutix Inc, sale 3,061 shares at $6.87 during a trade that took place back on Feb 24 ’25, which means that Heier Jeffrey S. is holding 265,998 shares at $21,029 based on the most recent closing price.
Stock Fundamentals for OCUL
Current profitability levels for the company are sitting at:
- -2.3 for the present operating margin
- 0.91 for the gross margin
The net margin for Ocular Therapeutix Inc stands at -2.84. The total capital return value is set at -0.31. Equity return is now at value -96.89, with -53.42 for asset returns.
Based on Ocular Therapeutix Inc (OCUL), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -1.5. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is -9.66.
Currently, EBITDA for the company is -66.42 million with net debt to EBITDA at 2.26. When we switch over and look at the enterprise to sales, we see a ratio of 12.04. The receivables turnover for the company is 2.03for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.01.
Conclusion
To put it simply, Ocular Therapeutix Inc (OCUL) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
